Novel interventions for Alzheimer’s disease

References

1. Jack Jr CR, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia. 2011;7(3):257-62.
2. Jack Jr CR, Wiste HJ, Weigand SD, Knopman DS, Mielke MM, Vemuri P, Lowe V, Senjem ML, Gunter JL, Reyes D, Machulda MM. Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain. 2015;138(12):3747-59.
3. Ravindranath V, Sundarakumar JS. Changing demography and the challenge of dementia in India. Nat Rev Neurol. 2021;17(12):747-
4. Lee J, Meijer E, Langa KM, Ganguli M, Varghese M, Banerjee J, Khobragade P. Prevalence of dementia in India: National and state estimates from a nationwide study. Alzheimer's & Dementia. 2023;19(7):2898-912.
5. Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold Spring Harbor Perspectives Med. 2012;2(8):a006239.
6. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer’s disease. Alzheimer's & dementia. 2007;3(3):186-91.
7. George NA, McKay FH. The public distribution system and food security in India. Int J Environ Res Pub Health. 2019;16(17):3221.
8. Karthivashan G, Ganesan P, Park SY, Kim JS, Choi DK. Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer’s disease. Drug Deliv. 2018;25(1):307-20.
9. Tariot PN. Memantine Study Group.: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Jama. 2004;291(3):317-24.
10. Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer’s disease. Neurotoxicity Res. 2013;24:358-
11. Standridge JB. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease. Clin Therapeutics. 2004;26(5):615-30.
12. Lleó A. Current therapeutic options for Alzheimer's disease. Curr Gen. 2007;8(8):550-8.
13. Ahamad SA, Dhuldhaj UP. Potential Plasma Biomarkers for Diagnosis of Alzheimer’s Disease: An Overview. Prog. Chem. Biochem. Res. 2024;7(2):114-28.
14. Jelic V, Darreh-Shori T. Donepezil: a review of pharmacological characteristics and role in the management of Alzheimer disease. Clinical Medicine Insights: Therapeutics. 2010;2:CMT-S5410.
15. S Doody R, L Cummings J, R Farlow M. Reviewing the role of donepezil in the treatment of Alzheimer's disease. Curr Alzheimer Res. 2012;9(7):773-81.
16. Olin J, Schneider L. Galantamine for Alzheimer's disease. Cochrane Database System Rev. 2002:1(3):CD001747.
17. Prvulovic D, Hampel H, Pantel J. Galantamine for Alzheimer's disease. Expert Opin Drug Metabtoxicol. 2010;6(3):345-54.
18. Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane database of systematic reviews. 2006(1): CD001747.
19. Alva G, Cummings J, Galvin J, Meng X, Somogyi M. P3–299: Infrequent skin reactions at the application site of the rivastigmine patch (4.6, 9.5 or 13.3 mg/24 h): Analysis of two clinical studies revealed most were tolerable and manageable across all doses. Alzheimer's & Dementia. Int J Clin Pract. 2015;69(5):518-30.
20. Dighe SN, De la Mora E, Chan S, Kantham S, McColl G, Miles JA. Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model. Commun Chemi. 2019;2(1):35.
21. Farlow M, Grossberg G, Sadowsky C, Meng X, Somogyi M. P3– 270: A 24‐week, open‐label extension to the ACTivities of daily living and cognitION (ACTION) study: Long‐term safety, tolerability and efficacy of a 13.3 mg/24 h rivastigmine patch in people with severe Alzheimer's disease. Alzheimer's & Dementia. 2013;9:p.655
22. Pooler AM, Polydoro M, Wegmann SK, Pitstick R, Kay KR, Sanchez L. Tau–amyloid interactions in the rTgTauEC model of 11 Kadam et al. / Journal of Pharmaceutical and Biological Sciences 2024;13(1):4-12 early Alzheimer's disease suggest amyloid‐induced disruption of axonal projections and exacerbated axonal pathology. J Comp Neurol. 2013;521(18):4236-48.
23. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging- Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's & dementia. 2011;7(3):263-9.
24. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey–Bloom J, Relkin N, Small GW, Miller B, Stevens JC. Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143-53.
25. Mf F. Mini‐mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-98.
26. Galvin JE, Roe CM, Powlishta KK, Coats MA, Muich SJ, Grant E, Miller JP, Storandt M, Morris JC. The AD8: a brief informant interview to detect dementia. Neurology. 2005 Aug 23;65(4):559-
27. Banerjee D, Muralidharan A, Mohammed AR, Malik BH. Neuroimaging in dementia: a brief review. Cureus. 2020;12(6): e8682.
28. Raji CA, Benzinger TL. The value of neuroimaging in dementia diagnosis. CONTINUUM: Lifelong Learning Neurol. 2022;28(3):800-21.
29. Adeli H, Ghosh-Dastidar S, Dadmehr N. Alzheimer's disease: models of computation and analysis of EEGs. Clin EEG and Neurosci. 2005;36(3):131-40.
30. Taylor J, Jaros M, Chen C, Harrison J, Hilt D. Plasma pTau181 Predicts Clinical Progression in a Phase 2 Randomized Controlled Trial of the 11β-HSD1 Inhibitor Xanamem® for Mild Alzheimer’s Disease. J Alzheimer's Dis. 2024:1-2:139-50.
31. Parra MA. Overcoming barriers in cognitive assessment of Alzheimer's disease. Dementia neuropsychologia. 2014;8(2):95-8.
32. Morris JC. Clinical assessment of Alzheimer's disease. Neurology. 1997;49(3):7-10.
33. McKhanna GM, Knopmanc DS, Chertkowd H, Hymanf BT, Jack Jr CR, Kawash CH. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-9.
34. Huff FJ, Boller F, Lucchelli F, Querriera R, Beyer J, Belle S. The neurologic examination in patients with probable Alzheimer's disease. Arch Neurol. 1987;44(9):929-32.
35. Galasko D, Kwo-on-Yuen PF, Klauber MR, Thal LJ. Neurological findings in Alzheimer's disease and normal aging. Arch Neurol. 1990;47(6):625-7.
36. Cohen D. The subjective experience of Alzheimer's disease: The anatomy of an illness as perceived by patients and families. Am J Alzheimer's Care Related Dis Res. 1991;6(3):6-11.
37. Wang Y, Wang Y, Zhu J, Guan Y, Xie F, Cai X. Systematic evaluation of urinary formic acid as a new potential biomarker for Alzheimer’s disease. Front Aging Neurosci. 2022;14:1046066.
38. Tong Z, Wang W, Luo W, Lv J, Li H, Luo H. Urine formaldehyde predicts cognitive impairment in post-stroke dementia and Alzheimer’s disease. J Alzheimer’s Dis. 2016;55(3):1031-8.
39. Anoop A, Singh PK, Jacob RS, Maji SK. CSF Biomarkers for Alzheimer′ s Disease Diagnosis. Int J Alzheimer’s Dis. 2010;(1):606802.
40. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature. 2009;461(7266):916-22.
41. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-44.
42. Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ. Association of low plasma Aβ42/Aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64(3):354-62.
43. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6(3):131-44.
44. Formichi P, Battisti C, Radi E, Federico A. Cerebrospinal fluid tau, Ass, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J Cellular Physiol. 2006;208(1):39-46.
45. Formichi P, Battisti C, Radi E, Federico A. Cerebrospinal fluid tau, Ass, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J cell Physiol. 2006;208(1):39-46.
46. Zhang Y, Wang L. Early diagnosis of Alzheimer’s disease using dual GAN model with pyramid attention networks. Connection Sci. 2024;36(1), 2321351.
47. Liu X Y, Yang LP, Zhao L. Stem cell therapy for Alzheimer's disease. World J Stem Cells. 2020;12(8):787.
48. Martello, G., & Smith, A. (2014). The nature of embryonic stem cells. Annual review of cell and Dev Biol, 30(1):647-75.
49. Fujikawa T., Oh S.H., Pi, L., Hatch HM, Shupe T, Petersen B.E. Teratoma formation leads to failure of treatment for type I diabetes using embryonic stem cell-derived insulin-producing cells. Am J Pathol. 2005;166(6):1781-91.
50. Formichi P, Battisti C, Radi E, Federico A. Cerebrospinal fluid tau, Ass, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J Cell Physiol. 2006;208(1):39-46.
51. Kim HJ, Seo SW, Chang JW, Lee JI, Kim CH, Chin J, Choi SJ, Kwon H, Yun HJ, Lee JM, Kim ST. Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase 1 clinical trial. Alzheimer's & Dementia: Trans Res Clin Interv. 2015;1(2):95-102.
52. Brookhouser N, Raman S, Potts C, Brafman DA. May I cut in? Gene editing approaches in human induced pluripotent stem cells. Cells. 2017;6(1):5.
53. Yun HM, Kim HS, Park KR, Shin JM, Kang AR, Song S, Kim YB, Han SB, Chung HM, Hong JT. Placenta-derived mesenchymal stem cells improve memory dysfunction in an Aβ1–42-infused mouse model of Alzheimer’s disease. Cell Death & Dis. 2013;4(12):e958.
54. Paull D, Sevilla A, Zhou H, Hahn AK, Kim H, Napolitano C, Tsankov A, Shang L, Krumholz K, Jagadeesan P, Woodard CM. Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells. Nat Methods. 2015;12(9):885-92.
55. Silverberg GD, Messier AA, Miller MC, Machan JT, Majmudar SS, Stopa EG. Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. Journal of Neuropathol Expe Neurol. 2010;69(10):1034-43.
56. Ja S. The regulation of rabbit skeletal muscle contraction. J. Biol. Chem. 1971;246:4866-71.
57. Pinheiro L, Faustino C. Therapeutic strategies targeting amyloid-β in Alzheimer’s disease. Curr Alzheimer Res. 2019;16(5):418-52.
58. Kang JM, Yeon BK, Cho SJ, Suh YH. Stem cell therapy for Alzheimer’s disease: a review of recent clinical trials. J Alzheimer's Dis. 2016;54(3):879-89.
59. Sontag E, Nunbhakdi-Craig V, Lee G, Brandt R, Kamibayashi C, Kuret J, White CL, Mumby MC, Bloom GS. Molecular interactions among protein phosphatase 2A, tau, and microtubules: implications for the regulation of tau phosphorylation and the development of tauopathies. J Biol Chem. 1999 Sep 3;274(36):25490-8.
60. Sontag E, Nunbhakdi-Craig V, Lee G, Brandt R, Kamibayashi C, Kuret J, White CL, Mumby MC, Bloom GS. Molecular interactions among protein phosphatase 2A, tau, and microtubules: implications for the regulation of tau phosphorylation and the development of tauopathies. Journal of Biological Chemistry. 1999;274(36):25490-
61. Petrushina I, Hovakimyan A, Harahap-Carrillo IS, Davtyan H, Antonyan T, Chailyan G, Kazarian K, Antonenko M, Jullienne A, Hamer MM, Obenaus A. Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first- in-human clinical trials. Neurobiol Dis. 2020;139:104823.
62. Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, Ward M, Friesenhahn M, Rabe C, Brunstein F, Quartino A. ABBY: 12 Kadam et al. / Journal of Pharmaceutical and Biological Sciences 2024;13(1):4-12 A phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018;90(21):e1889-97.
63. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, Maier M. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50-6.
64. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. New Engl J Medi. 2014;370(4):311-21.
65. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316(5825):750-4.
66. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science. 2007;316(5825):750-4.
67. Ahmad F, Karan A, Sharma R, Sharma NS, Sundar V, Jayaraj R, Mukherjee S, DeCoster MA. Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease. Ageing Res Rev. 2024:102229.
68. Beshir SA, Hussain N, Menon VB, Al Haddad AH, Al Zeer RA, Elnour AA. Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review. Int J Alzheimer’s Dis. 2024;2024(1):2052142.
69. Beshir SA, Hussain N, Menon VB, Al Haddad AH, Al Zeer RA, Elnour AA. Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review. Int J Alzheimer’s Dis. 2024;2024(1):2052142.
70. Nilsson P, Iwata N, Muramatsu SI, Tjernberg LO, Winblad B, Saido TC. Gene therapy in Alzheimer’s disease–potential for disease modification. Journal of cellular and molecular medicine. 2010;14(4):741-57.
71. Santos SG, Santana JV, Maia Jr FF, Lemos V, Freire VN, Caetano EW, Cavada BS, Albuquerque EL. Adsorption of ascorbic acid on the C60 fullerene. J Physi Chem B. 2008;112(45):14267-72.
72. Nazem A, Mansoori GA. Nanotechnology for Alzheimer's disease detection and treatment. Insciences J. 2011;1(4):169-93.
73. Kassem LM, Ibrahim NA, Farhana SA. Nanoparticle therapy is a promising approach in the management and prevention of many diseases: does it help in curing Alzheimer disease?. J Nanotechnol. 2020(1):8147080.
74. Zhang S, Gelain F, Zhao X. Designer self-assembling peptide nanofiber scaffolds for 3D tissue cell cultures. Semin Cancer Biol. 2005:15(5):413-20.
75. Ellis-Behnke RG, Liang YX, You SW, Tay DK, Zhang S, So KF. Nano neuro knitting: Peptide nanofiber scaffold for brain repair and axon regeneration with functional return of vision": Correction. Proc Natl Acad Sci USA. 2006;103(13):5054-9
76. McKenzie JL, Waid MC, Shi R, Webster TJ. Decreased functions of astrocytes on carbon nanofiber materials. Biomaterials. 2004;25(7- 8):1309-17.